NewAmsterdam Pharma Company N.V. (NAMS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone. My name is June and I will be your conference operator today. At this time, we would like to welcome you to the new Amsterdam Prevail update call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, and if you have joined via the webinar, please use the raised hand icon, which can be found at the bottom of your webinar application. At this time, I would like to turn the call over to Matthew Phillippe, Executive Vice President, Head of Investor Relations. Thank you, and good morning, everybody. Thanks for joining our call today. I'm excited to have Michael Davidson, CEO, John Kastelein, Chief Scientific Officer, and Ian Samaya, our Chief Financial Officer, on the call today. The presentation we'll be discussing is available on our investor site, so please feel free to access it there. However, before we begin, I let Michael share some exciting news. I would like to remind everyone and direct everyone to slide two and remind that this call will contain forward-looking statements within the meaning of federal securities law. These statements may include but are not limited to those related to potential clinical benefits of our product candidates, our clinical trial progress and design, and our expectations regarding the contemplated interim analysis of our prevailed trial and trial completion. Each of these forward-looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those in such statements. These risks and uncertainties are discussed in our annual report on Form 10-K filed with the Securities and Exchange Commission on February 18, 2026, and in s...